![[APHA]](/images/logo_apha.svg){kind=logo}
An innovative tool for providing more precise radiation treatment is being trialled by Australia's leading dedicated cancer care provider, Icon Group.
Icon will test software that aims to accurately measure patients' radiotherapy dose daily and ensure they receive the right treatment at the right time for their anatomy.
Dose Review, developed by Australian medical software start-up SeeTreat, will be evaluated at two Queensland sites:Icon Cancer Centre ToowoombaandIcon Cancer Centre Greenslopes.
The companies will work together to make the product suitable for widespread use once commercially released in early 2025. It does not yet have Therapeutic Goods Administration clearance.
"We're excited to be working with a 'homegrown' Australian innovator who is breaking new ground in radiotherapy innovation and developing software with a focus on improving workflow for clinical teams and most importantly quality of care," said Icon Group's Executive Manager of Clinical Care, Trent Aland.
"We're looking forward to trialling this software and hopefully adding it to Icon's leading fleet of radiotherapy technology and improving access to the latest in cancer care across Australia."
Read more: Icon-Bays deal boosts care for cancer patients
Read more: Icon Group joint venture offers more cancer treatment options
Next Safety And Quality:
17/9/2024 Icon trials aim to improve patient care
Previous Safety And Quality:
20/8/2024 Virtual heart service wins national prize